Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Abstract

In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.).

Keywords

Affiliated Institutions

• Jacksonville College US
• University of Pittsburgh US
• University of California, Los Angeles US
• South Texas Accelerated Research Therapeutics US
• Institut Gustave Roussy FR
• Angeles Clinic and Research Institute US
• Moffitt Cancer Center US
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Dana-Farber Cancer Institute US
• The University of Texas MD Anderson Cancer Center US
• The University of Sydney AU
• Westmead Hospital AU
• University of Pennsylvania US
• University of California, San Francisco US
• Memorial Sloan Kettering Cancer Center US
• Mayo Clinic in Arizona US
• Princess Margaret Cancer Centre CA
• Melanoma Institute Australia AU
• WinnMed US

Related Publications